Breast cancer (early) - hormonal treatments (TA112)
Fast, easy summary view of NICE guidance on 'early and locally advanced breast cancer'
Anastrozole, exemestane and letrozole are recommended as possible treatments for women who have a type of breast cancer called early oestrogen-receptor-positive breast cancer and have been through the menopause. Anastrozole, exemestane or letrozole may be given as an 'extra' treatment (called an adjuvant treatment), after the woman has had an operation to remove the cancer, to help to stop the cancer coming back.
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: early and locally advanced breast cancer
This page was last updated: 25 June 2012
Information for the public
Implementation tools and resources
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.